These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 20131232)
1. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Jung H; Bobba R; Su J; Shariati-Sarabi Z; Gladman DD; Urowitz M; Lou W; Fortin PR Arthritis Rheum; 2010 Mar; 62(3):863-8. PubMed ID: 20131232 [TBL] [Abstract][Full Text] [Related]
2. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Shinjo SK; Bonfá E; Wojdyla D; Borba EF; Ramirez LA; Scherbarth HR; Brenol JC; Chacón-Diaz R; Neira OJ; Berbotto GA; De La Torre IG; Acevedo-Vázquez EM; Massardo L; Barile-Fabris LA; Caeiro F; Silveira LH; Sato EI; Buliubasich S; Alarcón GS; Pons-Estel BA; Arthritis Rheum; 2010 Mar; 62(3):855-62. PubMed ID: 20131238 [TBL] [Abstract][Full Text] [Related]
3. Factors associated with osteonecrosis in Thai lupus patients: a case control study. Uea-areewongsa P; Chaiamnuay S; Narongroeknawin P; Asavatanabodee P J Clin Rheumatol; 2009 Oct; 15(7):345-9. PubMed ID: 20009970 [TBL] [Abstract][Full Text] [Related]
4. Discontinuation of antimalarial drugs in systemic lupus erythematosus. Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401 [TBL] [Abstract][Full Text] [Related]
5. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Sisó A; Ramos-Casals M; Bové A; Brito-Zerón P; Soria N; Muñoz S; Testi A; Plaza J; Sentís J; Coca A Lupus; 2008 Apr; 17(4):281-8. PubMed ID: 18413408 [TBL] [Abstract][Full Text] [Related]
6. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. Akhavan PS; Su J; Lou W; Gladman DD; Urowitz MB; Fortin PR J Rheumatol; 2013 Jun; 40(6):831-41. PubMed ID: 23588942 [TBL] [Abstract][Full Text] [Related]
7. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Kreuter A; Gaifullina R; Tigges C; Kirschke J; Altmeyer P; Gambichler T Arch Dermatol; 2009 Mar; 145(3):244-8. PubMed ID: 19289751 [TBL] [Abstract][Full Text] [Related]
8. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Tektonidou MG; Laskari K; Panagiotakos DB; Moutsopoulos HM Arthritis Rheum; 2009 Jan; 61(1):29-36. PubMed ID: 19116963 [TBL] [Abstract][Full Text] [Related]
9. Risk for incident arterial or venous vascular events varies over the course of systemic lupus erythematosus. Chang ER; Pineau CA; Bernatsky S; Neville C; Clarke AE; Fortin PR J Rheumatol; 2006 Sep; 33(9):1780-4. PubMed ID: 16832849 [TBL] [Abstract][Full Text] [Related]
10. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. Parke A; West B J Rheumatol; 1996 Oct; 23(10):1715-8. PubMed ID: 8895146 [TBL] [Abstract][Full Text] [Related]
11. Antimalarial drugs, systemic lupus erythematosus and pregnancy. Parke AL J Rheumatol; 1988 Apr; 15(4):607-10. PubMed ID: 3397970 [TBL] [Abstract][Full Text] [Related]
12. Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs. López P; Gómez J; Mozo L; Gutiérrez C; Suárez A Arthritis Res Ther; 2006; 8(2):R42. PubMed ID: 16507146 [TBL] [Abstract][Full Text] [Related]
13. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Wallace DJ; Linker-Israeli M; Metzger AL; Stecher VJ Lupus; 1993 Feb; 2 Suppl 1():S13-5. PubMed ID: 8485565 [TBL] [Abstract][Full Text] [Related]
14. Thrombovascular events in systemic lupus erythematosus: comment on the article by Jung et al. Wallace DJ Arthritis Rheum; 2010 Sep; 62(9):2824; author reply 2824-5. PubMed ID: 20872599 [No Abstract] [Full Text] [Related]
15. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. Somers E; Magder LS; Petri M J Rheumatol; 2002 Dec; 29(12):2531-6. PubMed ID: 12465147 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. Bessant R; Duncan R; Ambler G; Swanton J; Isenberg DA; Gordon C; Rahman A Arthritis Rheum; 2006 Dec; 55(6):892-9. PubMed ID: 17139666 [TBL] [Abstract][Full Text] [Related]
17. Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study. Cooper GS; Dooley MA; Treadwell EL; St Clair EW; Gilkeson GS Arthritis Rheum; 2002 Jul; 46(7):1830-9. PubMed ID: 12124867 [TBL] [Abstract][Full Text] [Related]
18. A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. Svenungsson E; Gustafsson J; Leonard D; Sandling J; Gunnarsson I; Nordmark G; Jönsen A; Bengtsson AA; Sturfelt G; Rantapää-Dahlqvist S; Elvin K; Sundin U; Garnier S; Simard JF; Sigurdsson S; Padyukov L; Syvänen AC; Rönnblom L Ann Rheum Dis; 2010 May; 69(5):834-40. PubMed ID: 19762360 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients. Zhang CY; Lu LJ; Li FH; Li HL; Gu YY; Chen SL; Bao CD J Clin Rheumatol; 2009 Apr; 15(3):111-6. PubMed ID: 19300290 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]